Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 7;8(2):214.
doi: 10.3390/jcm8020214.

Effects of Different Comorbidities on Health-Related Quality of Life among Respiratory Patients in Vietnam

Chau Quy Ngo  1 , Phuong Thu Phan  2 , Giap Van Vu  3 , Quyen Le Thi Pham  4 , Long Hoang Nguyen  5 , Giang Thu Vu  6 , Tung Thanh Tran  7 , Huong Lan Thi Nguyen  8 , Bach Xuan Tran  9   10 , Carl A Latkin  11 , Cyrus S H Ho  12 , Roger C M Ho  13   14
Affiliations

Effects of Different Comorbidities on Health-Related Quality of Life among Respiratory Patients in Vietnam

Chau Quy Ngo et al. J Clin Med. .

Abstract

Comorbidities are common in respiratory disease patients and have been well-known to impact their quality of life. The objective of this study is to estimate the minimal clinically important difference (MCID) of the health-related quality of life (HRQOL) among respiratory disease patients with different comorbidities in a Vietnamese tertiary hospital. We performed a cross-sectional study from October to November 2016 at the Respiratory Center of Bach Mai Hospital, Hanoi, with a total of 508 participants. Information about socio-economic characteristics, HRQOL and comorbidities of participants was collected. ANOVA was used to identify MCID between patients with and without specific comorbid conditions. Tobit regression was used to explore the associations between comorbidities and the HRQOL. Results showed that the prevalence of cardiovascular comorbidities was 23.8%, followed by musculoskeletal diseases (12.0%), digestive diseases (11.8%), endocrine diseases (10.0%), kidney diseases (5.1%) and ear, nose, and throat diseases (4.5%). Regarding HRQOL, having a problem in pain/discomfort was observed in 61.0% of participants, followed by anxiety/depression (48.2%). Mean EQ-5D index was 0.66 (SD (Standard Deviation) = 0.31). The significant MCID (p < 0.05) was found between patients with and without cardiovascular diseases, musculoskeletal diseases, kidney diseases, and endocrine diseases. The multivariate regression model showed that only musculoskeletal diseases were found to be related with the marked decrement of EQ-5D index score (Coef. = -0.13; 95% CI (Confident Interval) = -0.23; -0.02). Suffering at least one chronic illness was correlated to the marked decrease of EQ-5D index score (Coef. = -0.09; 95%CI = -0.17; -0.01). These results underline the importance of appropriate pain management as well as the provision of an interprofessional care approach to patients in order to alleviate the burden of comorbidities to their treatment outcomes and HRQOL.

Keywords: HRQOL; Vietnam; comorbidity; minimally clinically important difference; respiratory diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

Figures

Figure 1
Figure 1
Proportion of patients reporting any problems in the Euroqol-5 dimensions-5 levels (EQ-5D-5L) dimensions by different chronic diseases.
Figure 2
Figure 2
EQ-5D-5L index by chronic conditions.
Figure 3
Figure 3
EQ-5D-5L dimensions and index according to the number of comorbidities.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization Chronic Respiratory Diseases. [(accessed on 12 December 2018)];2017 Available online: https://www.who.int/respiratory/en/
    1. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., Fukuchi Y., Jenkins C., Rodriguez-Roisin R., van Weel C., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007;176:532–555. doi: 10.1164/rccm.200703-456SO. - DOI - PubMed
    1. Cazzola M., MacNee W., Martinez F.J., Rabe K.F., Franciosi L.G., Barnes P.J., Brusasco V., Burge P.S., Calverley P.M., Celli B.R., et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur. Respir. J. 2008;31:416–469. doi: 10.1183/09031936.00099306. - DOI - PubMed
    1. Burgel P.R., Escamilla R., Perez T., Carre P., Caillaud D., Chanez P., Pinet C., Jebrak G., Brinchault G., Court-Fortune I., et al. Impact of comorbidities on COPD-specific health-related quality of life. Respir. Med. 2013;107:233–241. doi: 10.1016/j.rmed.2012.10.002. - DOI - PubMed
    1. Koskela J., Kilpelainen M., Kupiainen H., Mazur W., Sintonen H., Boezen M., Lindqvist A., Postma D., Laitinen T. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. BMC Pulm. Med. 2014;14:102. doi: 10.1186/1471-2466-14-102. - DOI - PMC - PubMed

LinkOut - more resources